Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback